同步和超时脑转移的流行病学和生存结果:一项以人口为基础的回顾性研究
Kelly Jiang1, Megan Parker1, Joshua Materi1
1Departments of1Neurosurgery.
Neurosurgical focus
|August 1, 2023
概括
大多数大脑转移 (BMs) 在初始癌症治疗后发生,而超时的BMs比同步的更频繁. 早期的抗瘤疗法可以改善BMs患者的生存结果.
科学领域:
- 在瘤学瘤学.
- 神经学 神经学
- 癌症研究 癌症研究
背景情况:
- 大脑转移 (BMs) 是最常见的内瘤.
- 确定BMs的患病率是具有挑战性的,因为许多研究只关注同步转移.
- 这项研究调查了10年来同步性和超时性BM的发生率和预后.
研究的目的:
- 为了确定同步和超时脑转移 (BMs) 的发生率和预后.
- 分析与不同类型的BMs相关的时间进程和生存结果.
- 评估抗瘤药物和放射治疗对BM发育和生存的影响.
主要方法:
- 利用TrinetX研究网络数据库从2013年1月1日到2023年1月1日的患者数据.
- 包括患有原发性癌症和随后的BM诊断的患者,将超慢性BM定义为发生在原发性癌症后>2个月.
- 员工倾向得分匹配和卡普兰-梅尔图分析生存差异,并使用日志等级测试和危险比率进行统计评估.
主要成果:
- 在11,497,663名患者中,有2.6%患有肌肉瘤,最常见的是肺癌,乳腺癌和黑色素瘤癌.
- 超慢性BMs (62.2%) 比同步性BMs (37.8%) 更常见.
- 超慢性BM诊断与比同步BM更长的存活率相关,但比没有BM的额外头骨转移更短的存活率;抗瘤疗法和放射治疗改善了生存结果.
结论:
- 大多数BMs呈现为超慢性,通常在初级癌症诊断后两年内出现.
- 脑膜瘤呈现的时间,特别是某些癌症的六个月内,可能会为未来的内分期建议提供信息.
- 在BM发育之前的抗瘤疗法可能会延迟转移并提高患者的存活率,突出显示在查,预防和治疗方面需要进一步的研究.
相关概念视频
01:21Cancer Survival Analysis
384
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
384
01:20Comparing the Survival Analysis of Two or More Groups
224
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
224
01:24Kaplan-Meier Approach
180
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
180
01:15Assumptions of Survival Analysis
156
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
156
01:18Introduction To Survival Analysis
282
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
282
01:20Actuarial Approach
97
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
97